Literature DB >> 28723468

Trends in Antibiotic Resistance in Urologic Practice.

Hala Kandil1, Emma Cramp2, Tejal Vaghela3.   

Abstract

CONTEXT: The significant global upsurge in antimicrobial resistance, particularly among Enterobacteriaceae, represents a serious threat to health care systems. The implications for urologic practice are of particular concern.
OBJECTIVE: To review trends in antibiotic resistance in urologic practice. EVIDENCE ACQUISITION: We report current European trends of resistance in Gram-negative uropathogens. EVIDENCE SYNTHESIS: In addition to β-lactam resistance, Gram-negative pathogens are often resistant to multiple drug classes, including aminoglycosides, fluoroquinolones, and carbapenems, commonly used to treat urologic infections. Interest is renewed in old antibiotics, and several new antibiotics are in the pipeline to meet the challenge of treating these infections. In this review, we summarise emerging trends in antimicrobial resistance and its impact on urologic practice. We also review current guidelines on the treatment and prevention of urologic infections with these organisms, and some key antibiotics in the era of resistance.
CONCLUSIONS: Increasing antimicrobial resistance represents a challenge to urologic practice for both treatment and prophylaxis. Antibiotic choice should be determined according to risk factors for multidrug resistance. Good knowledge of the local microbial prevalence and resistance profile is required to guide antimicrobial therapy. PATIENT
SUMMARY: Antimicrobial resistance represents a challenge in urology. We summarise emerging trends in antimicrobial resistance and review current guidelines on the treatment and prevention of urologic infections, as well as some key antibiotics in the era of resistance.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute pyelonephritis; Antimicrobial resistance; Catheter-associated urinary tract infection; Complicated urinary tract infection; Prostatitis; Transurethral prostate biopsy; Uncomplicated urinary tract infection; Urologic infections

Year:  2016        PMID: 28723468     DOI: 10.1016/j.euf.2016.09.006

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  9 in total

1.  Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal.

Authors:  Ganendra Bhakta Raya; Bhim Gopal Dhoubhadel; Dhruba Shrestha; Sunayana Raya; Ujjwal Laghu; Ashok Shah; Bijendra Bhakta Raya; Rita Kafle; Christopher M Parry; Koya Ariyoshi
Journal:  Trop Med Health       Date:  2020-08-03

Review 2.  Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.

Authors:  Oskar Estradé; Valvanera Vozmediano; Nerea Carral; Arantxa Isla; Margarita González; Rachel Poole; Elena Suarez
Journal:  Antibiotics (Basel)       Date:  2022-05-11

3.  In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.

Authors:  Marguerite L Monogue; Sara Giovagnoli; Caterina Bissantz; Claudia Zampaloni; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Topical rectal antiseptic at time of prostate biopsy: how a resident patient safety project has evolved into institutional practice.

Authors:  Rosa Park; Justin Gyorfi; Kalyan Dewan; Girish Kirimanjeswara; Joseph Y Clark; Matthew G Kaag; Kathleen Lehman; Jay D Raman
Journal:  Int Urol Nephrol       Date:  2018-07-17       Impact factor: 2.370

5.  Zishenwan Decreases Kidney Damage in Recurrent Urinary Tract Infection through the Inhibition of Toll-Like Receptor 4 Signal.

Authors:  Guoqiang Liang; Hua Tang; Daolei Ni; Yan Ren; Chenxi Zhang; Wenyi Zheng; Yongliang Song; Xiaofeng Shen; Weimin Jin; Chunbo Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-05       Impact factor: 2.629

6.  Contribution of acrB upregulation & OmpC/Ompk36 loss over the presence of blaNDM towards carbapenem resistance development among pathogenic Escherichia coli & Klebsiella spp.

Authors:  Arijit Pal; Lena Dhara; Anusri Tripathi
Journal:  Indian J Med Res       Date:  2019-04       Impact factor: 2.375

7.  A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.

Authors:  Ying Li; Yousheng Yin; Xiaomei Peng; Hongguang Zheng; Fajun Fu; Zhenxiang Liu; Xiongfei Wu; Xiaoyan Wu; Song Zheng; Nan Chen; Leye He; Laicheng Ren; Zhaohui Ni; Detian Li; Peiyu Liang; Xiaoju Lv; Yingyuan Zhang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

8.  Current antibiotic resistance patterns of rare uropathogens: survey from Central European Urology Department 2011-2019.

Authors:  Jan Hrbacek; Pavel Cermak; Roman Zachoval
Journal:  BMC Urol       Date:  2021-04-13       Impact factor: 2.264

9.  Comparison of a combined regimen of fosfomycin and ciprofloxacin with ciprofloxacin alone as antimicrobial prophylaxis for transrectal prostate biopsy in the era of high fluoroquinolone-resistant rectal flora.

Authors:  Do Gyeong Lim; Seung Il Jung; Myung Soo Kim; Ho Seok Chung; Eu Chang Hwang; Dong Deuk Kwon
Journal:  Prostate Int       Date:  2021-04-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.